Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target : Clinical Journal of the American Society of Nephrology

Journal Logo

In-Depth Reviews: In-Depth Reviews

Familial Renal Glucosuria and SGLT2

From a Mendelian Trait to a Therapeutic Target

Santer, René*; Calado, Joaquim†,‡

Author Information
Clinical Journal of the American Society of Nephrology 5(1):p 133-141, January 2010. | DOI: 10.2215/CJN.04010609
  • Free


Glucose is the primary energy source for brain, muscle, and other organs. Membrane lipid bilayers, however, are virtually impermeable to hydrophilic glucose molecules and rely on glucose transporters to facilitate their movement across cell membranes and their distribution to and within various tissues (1,2). The kidney contributes to glucose homeostasis by reabsorbing approximately 180 g from the glomerular filtrate each day. Because of the activity of glucose transporters in the renal proximal tubule, <0.5 g/d (range 0.03 to 0.3 g/d) is excreted in the urine of healthy adults (1,2).

There are two means of glucose transport, facilitative and secondary active transport, each of which involves different classes of transporters. Facilitative transport, which is driven by the concentration gradient across cellular membranes, occurs in essentially all cell types and is mediated by members of the GLUT transporter family. Secondary active transport is the first step in transcellular glucose transport in the intestine and kidney and is mediated by members of the SGLT transporter family. GLUTs are encoded by the SLC2 genes, whereas SGLTs are encoded by the SLC5 genes. It is possible that other transporters may account for additional glucose transport activity in the kidney. For instance, mutations in the monocarboxylate transporter MCT12, encoded by the SLC16A12 gene, were found to be responsible for an autosomal dominant inherited condition characterized by juvenile cataracts with microcornea and mild renal glucosuria (OMIM 612018), underlining the role of transporters other than the GLUTs and SGLTs in renal glucose handling (3).

There are >220 members in the SLC5 family, also known as the sodium substrate symporter gene family (SSSF); of these, 12 have been identified in the human genome (4,5). SGLT members are multifunctional membrane-bound proteins that display a vast array of functions from sodium-coupled co-transport for sugars, monocarboxylates, amino acids, vitamins, osmolytes, and ions to sodium uniporter activity, channels for urea and water, glucose sensing, and tumor suppression (4,5).

At least two sodium-coupled glucose transporters, SGLT1 and SGLT2, play an important role in the apical membrane of proximal tubular cells in the kidney (Figure 1). These transporters first bind Na+, before they bind glucose, and the electrochemical Na+ gradient generated by the Na+/K+-ATPase is the driving force for the symporter activity. SGLT1 is predominantly expressed in enterocytes (6). Its primary function here is to mediate active glucose and galactose transport across the apical membrane at low sugar concentration, but it also mediates expression of facilitative transporters at high glucose concentration. Although not involved in resorption of the bulk of glucose in the kidney, the kinetic characteristics of SGLT1 are favorable for transport of glucose when present at low concentrations. In addition to the intestine and kidney, SGLT1 is expressed in organs such as the brain and the heart.

Figure 1:
A model for Na+/glucose transport in the kidney. SGLT2 is predominantly expressed in the S1 segment of the proximal tubule and is responsible for the vast majority of glucose reabsorption from urine.

SGLT2 expression occurs predominantly in the luminal brush border of the proximal tubule of the renal cortex, where it is the principal transporter that mediates glucose resorption (7) (Table 1). It is also expressed to a much lower degree in other organs, including the liver. SGLT4, SGLT5, SGLT6, and SMIT1 are expressed in several tissues, including the kidney, and a putative role in glucose transport in the kidney is anticipated but has yet to be shown. SGLTs are multifunctional proteins, and for the remaining six products of SLC5 genes that are predicted to exist in the human genome, different functions have been reported. For instance, SGLT3, initially assigned to be a co-transporter on the basis of sequence homology, was later characterized as a glucose-gated ion channel expressed in cholinergic neurons and the neuromuscular junction (8) and might play a role in diet-triggered intestinal motility.

Table 1:
Substrates and distribution of human glucose transporters

Location and Relative Affinities of Renal SGLTs for Glucose

SGLT2 and SGLT1 can be distinguished by their affinities for glucose and Na+ and their location in the kidney (912). SGLT2 is expressed exclusively near the early proximal convoluted tubule (termed S1) (13), whereas SGLT1 is expressed near the medullary proximal tubule (termed S3) (911). SGLT2 is a low-affinity, high-capacity glucose transporter, whereas SGLT1 is a high-affinity, low-capacity glucose transporter. SGLT1 transports glucose and galactose (10), has a K0.5 for glucose of approximately 0.4 mM, and carries two molecules of Na+ for every molecule of glucose. SGLT1 has a K0.5 of approximately 3 mM for Na+ (14). SGLT2 has a K0.5 for glucose of approximately 2 mM, carries one molecule of Na+ for every molecule of glucose, and has a K0.5 for Na+ of 100 mM (14). SGLT2, unlike SGLT1, does not transport galactose. Thus, the bulk of glucose is reabsorbed at the S1 segment by the high-capacity SGLT2 transporter, whereas the remaining glucose that enters the S3 segment is reabsorbed by the high-affinity SGLT1 transporter; together they minimize glucose loss in the urine (14).

SGLT Protein Structure and Transport Dynamics

Human SLC5 genes code for proteins with a molecular mass of approximately 75 kD. They exhibit considerable functional similarity, despite that transported solutes are variable. The topology and secondary structure model of SGLT1, the most extensively studied member of the SSSF group, has been experimentally delineated by extensive analyses of its primary sequence, sequence comparison, computational prediction methods, and both functional and electron microscopic assays performed in heterologous expression systems (2,4,15,16). The membrane topology of other members of the SGLT family is anticipated to be similar on the basis of their common ancestry, function, and similar primary sequences. SGLT2, which is composed of 672 amino acids, bears 59% identity with the 664 amino acids that constitute SGLT1 (17). In general, cytoplasmic domains are better conserved than extracellular domains among SGLTs.

The members of the SGLT family share a common core of 13 transmembrane helices (TMH), although some members have one or two additional C-terminal helices. SGLT1 and SGLT2 both have 14 TMHs with both the hydrophobic N- and C-terminal domains lying extracellular (2). The SSSF consensus sequence [GS]-2(2)-[LIY]-x(3)-[LIVMFYWSTAG](7)-x(3)-[LIY]-[STAV]-x(2)-G-G-[LMF]-x-[SAP] lies in TMH5. In addition, the smaller eukaryote SGLTs and SMIT subfamily members share an R-x-T-x(4)-F-L-A-G-x(4)-W-W-x(2)-G-A-S motif near the N-terminal domain, proximal in TMH2.

The crystal structure of vSGLT, a sodium-galactose symporter from Vibrio parahaemolyticus and a member of the SSSF, was reported recently (18). The protein assembles as a tightly packed parallel dimer, although previous work has shown that SGLT1 is fully functional as a monomer. The structural core is formed from inverted repeats of five TMHs (2 through 6 and 7 through 11; Figure 2A). Seven TMHs (2 through 4, 7 through 9, and 11) contribute to side-chain interaction for ligand selectivity. Extracellular and intracellular gates delineating the galactose pathway were identified, with residues M73, Y87, and F424 forming the extracellular and Y263, Y262, and W264 forming the intracellular ones. There is a plausible Na+-binding site at the intersection of TMH2 and TMH9, approximately 10 Å away from the substrate-binding site. External Na+ binds first, which facilitates TMH2 rearrangements to form the substrate-binding site. Galactose binding induces the formation of the extracellular gate and enlarges the intracellular cavity by conformational changes in TMH3, TMH4, TMH7 and 8, and TMH9 through 11. Finally, displacement of Y263 releases Na+ and then galactose intracellularly (Figure 2B).

Figure 2:
Structure of vSGLT. (A) Topology. The structure is colored as a rainbow from the N-terminus (red) to the C-terminus (purple). The blue and red trapeziums represent the inverted topology of TMH2 through TMH6 and TMH7 through TMH11. The gray hexagon with red outline represents galactose. Residues involved in sugar recognition, gate residues, and a proposed Na+ site are shown in cyan, gray, and yellow circles. (B) Alternating accessibility. (Left) Slice through surface of the outward-facing model viewed from the membrane plane showing the extracellular cavity (blue mesh). (Right) Slice through surface of the inward-facing structure in the membrane plane showing the intracellular cavity (blue mesh). Helices showing structural rearrangement are colored orange, green, and blue for helices TMH3, TMH7, and TMH11, respectively; helices with little movement are colored white. The surface is shown in beige. Galactose is shown as black and red spheres for the C and O atoms, respectively. Y263 and the Na+ ion are colored as gray and blue spheres, respectively. Reprinted from reference (18), with permission.

Other Functions of SGLTs

In addition to their role in sugar transport, SGLTs can function as uniporters. SGLT1, SGLT3, and SGLT5 transport Na+ in the absence of sugar (19). SGLT3 functions as a glucose sensor in visceral neuronal cells (8). SGLT1 and other co-transporters have been shown to function as channels for water and other small hydrophilic solutes when expressed in oocytes (20,21) and are proposed to play an important role in fluid and urea transport across the intestine. SGLT1 has been shown to play a significant role in water transport across the intestinal brush border membrane by either co-transporting water along with Na+ and glucose or by osmosis (20,22,23). SGLT1 does not simply mediate secondary active transport at the apical membrane of enterocytes itself but also regulates other glucose transport mechanisms, such as promoting insertion of GLUT2 into the apical membrane to provide a facilitative component of absorption up to three times greater than that of SGLT1 alone to match dietary intake of carbohydrates (24).

Regulation of SGLT2 Expression and Activity (in Diabetes)

It was previously shown that patients with type 1 diabetes had a significant increase in the renal transport maximum for glucose (25), and several rodent models of diabetes have shown upregulation of the GLUT2 protein in the renal proximal tubules of diabetic animals with long-term hyperglycemia, supporting the need for higher glucose efflux and glucose reabsorption (26,27). It is interesting that no changes in the SGLT1 protein expression were detected (27). Regarding SGLT2 expression, however, studies have been hampered by the lack of suitable antibodies.

Renal proximal cells isolated from the urine of patients with type 2 diabetes displayed an elevation of SGLT2 mRNA compared with healthy individuals (28), and in a rat model of diabetes, SGLT2 and hepatocyte nuclear factor 1α (HNF1α) mRNA expression was increased but reversed upon treatment with insulin or phlorizin, an inhibitor of SGLTs (29). Similar changes have been reported for GLUT2 in diabetic rats at day 6 of treatment with either insulin or phlorizin (30). HNF1α is a transcriptional activator encoded by the TCF1 gene, found to be mutated in maturity-onset diabetes of the young type 3 (MODY3), an autosomal dominant form of non–insulin-dependent diabetes (31). Defective renal glucose resorption in several families with MODY3, including in some euglycemic members, has been described (32,33). HNF1α−/− homozygous mice, compared with wild-type or heterozygous healthy littermates, displayed deficient insulin secretion and hyperglycemia (34); however, plasma glucose concentrations were lower than expected in light of the severity of the insulin secretory defect, probably secondary to the associated glucose resorption defect detected in these mice (3335). SGLT2 expression has been shown in murine systems to be controlled by HNF1α, and HNF1α binding sites have been identified in the mouse SLC5A2 gene promoter (29,33); therefore, plasma glucose concentration seems to be an important modulator of SGLT2 activity, and this activity may be in part regulated by HNF1α expression.

Familial Renal Glucosuria

Glucosuria can occur in the setting of global dysfunction of the proximal tubule, known as the Fanconi-de Toni-Debré syndrome, or renal Fanconi syndrome. Glucosuria in this instance accompanies the excessive urinary excretion of amino acids, phosphate, bicarbonate, and other solutes that typically are reabsorbed in the proximal tubule. The occurrence of glucosuria in the absence of both generalized proximal tubular dysfunction and hyperglycemia is known as renal glucosuria and recognized as an inherited disorder and hence the designation of familial renal glucosuria (FRG).

Diagnostic Criteria and Mode of Inheritance

Depending on the diagnostic criteria used, different prevalences and modes of inheritance were reported for FRG. Initial investigations used a nonquantitative assessment of glucosuria after an oral glucose tolerance test as a diagnostic technique (36). Under these circumstances, evidence emerged for an autosomal dominant inheritance. When later this technique was applied for screening purposes, an incidence of renal glucosuria in the general population of 0.29% was proposed (37). Marble in 1947 (38) defined more stringent diagnostic criteria, and the condition was reported to be autosomal recessive and uncommon. These revised criteria included a normal oral glucose tolerance test in regard to plasma glucose concentration, normal plasma levels of insulin, free fatty acids, glycosylated hemoglobin, and relatively stable urinary glucose levels (10 to 100 g/d; except during pregnancy, when it may increase) with glucose present in all urine samples. Urine should contain glucose as the only source of carbohydrate, and individuals should have normal carbohydrate storage and use (38). By the mid-1950s, renal titration studies delineated renal glucosurias into type A and type B (39). Patients with type A renal glucosuria are characterized by a low renal threshold for glucose and a low maximum tubular glucose reabsorption in contrast to individuals with FRG type B, who have a low threshold but still can reach a normal maximum tubular glucose reabsorption, causing an abnormal splay of their filtration-resorption curve (Figure 3). Later, the complete absence of renal glucose transport was found in very few individuals and designated as type O glucosuria (40). Glucose quantification in the collected urine 2 to 4 h after a glucose load of 50 g in three pedigrees gave the first insight that the mode of inheritance for FRG could be one of co-dominance: Individuals supposed to be homozygous for the condition had persistent heavy glucosuria and experienced “renal glucosuria,” whereas putative heterozygotes had mild (or no glucosuria) and had only the “renal glucosuria trait” (41). Elsas and Rosenberg (42) reported that both type A and type B renal glucosuria could be observed in the same family and that both parents could be completely normal or show an abnormality in renal tubular glucose transport. They postulated that this could be due to the variable expression of a dominant mutation or, alternatively, that two different genes could be involved: A mutant B gene that leads to decreased affinity of a glucose transporter for glucose and a mutant A gene that leads to reduced transport capacity.

Figure 3:
Correlation between glomerular glucose load and tubular glucose reabsorption (TG) in various renal glucosurias. TmG, maximum tubular glucose reabsorption; PG, plasma glucose concentration. The hatched area is the splay—the difference between actual and ideal reabsorption that is exhibited when the reabsorption curve shows a nonlinear transition as the TmG is reached. Redrawn from reference (72), with permission.

Characterization of FRG into types A/B/O is presented here mainly for historical reasons. Current molecular findings have enabled appropriate genotype–phenotype correlations in the vast majority of cases and, consequently, a simpler and easier classification in FRG.

Molecular Genetics

Since SLC5A2 was cloned and the delineation of the major renal resorptive mechanism for glucose made apparent, this transporter was implicated as a major candidate gene for FRG (7). The first mutation in the SLC5A2 gene, positioned in 16p11.2, was reported by Santer et al. (43), and more case series have confirmed that mutations in SLC5A2 are indeed responsible for the large majority of cases of FRG (4446). Additional support has come from several case reports (4751).

Although the pattern of inheritance that best fits FRG is one of co-dominance, surprisingly, increased glucose excretion was not observed in all individuals with similar or identical mutations, heterozygosity for mutations in particular, suggesting a role of nongenetic factors or other genes in renal glucose transport. Furthermore, in only a few patients with FRG does the renal excretion approach the filtered load (e.g., in the original patient with familial renal glucosuria type O and homozygosity for a premature stop codon [347X]); however, other patients with truncating mutations (e.g., p.W440X) were found to excrete only approximately half the filtered load. This again suggests that other transporters under certain circumstances may reabsorb a significant amount of glucose in these patients. In particular, other SGLTs that are known to be expressed in the kidney and whose functions have not yet been clarified are candidates for modifier genes in FRG. At least three patients have been reported not to have any mutation identified after sequencing of the entire coding region of SLC5A2 (44,45), which also raises the possibility of genetic heterogeneity. Indeed, a locus on chromosome 6, in close genetic linkage with the HLA complex, has been positioned and named GLYS1 on the basis of segregation analysis in five unrelated affected pedigrees (52); however, this hypothetical gene remains to be cloned. Alternatively, mutations in the promoter region or heterozygosity for large deletions that are not detectable by PCR may also account for those findings.

Analysis of the genomic structure of human SGLT2 revealed a 14-exon gene that spans 8 kb with an intron-exon organization that is similar to SGLT1 (44). All of the introns display the donor and acceptor splice consensus sequences GT/AG, and a previously unreported CA repeat was identified in intron 1. The 2019-bp coding sequence accurately predicts the 672-residue SGLT2 protein previously reported after cloning of SGLT2 from a human kidney cDNA library (17). There are no reports of splice variants or isoforms.

Genotype–Phenotype Correlations in FRG

Establishing definite genotype–phenotype correlations in FRG is a difficult task because of the variable expressivity and because other genes may have an impact on overall renal glucose resorption. In general, patients with mild glucosuria (<10 g/1.73 m2 per d) will usually be heterozygous for SGLT2 mutations, both nonsense and missense, although, as previously stated, this may not happen in all carriers of such mutations. Cases of severe glucosuria (≥10 g/1.73 m2 per d) show the characteristics of autosomal recessive inheritance with homozygosity or compound heterozygosity for SGLT2 mutations (4446).

Forty-four different mutations, scattered throughout the SCL5A2 gene, have been reported, with most being private (46) (Figure 4). Among them are missense and nonsense mutations, small deletions (in-frame and frame shift), and splicing mutations. IVS7 + 5G may be considered a mutational hot spot because of the recurrent finding of the IVS7 + 5G→A allele in several unrelated families who have FRG and are of different ethnic origin (44,46).

Figure 4:
Mutation analysis of the human Na+/glucose co-transporter gene SLC5A2 that encodes SGLT2. Transmembrane domains 1 through 14 are shown as dark gray boxes. Redrawn from reference (46), with permission.

Molecular analysis may also be helpful in understanding the findings of earlier titration studies. Haploinsufficiency will result in a reduced number of normally functioning carriers in the renal tubule, thereby leading to type A glucosuria, whereas certain missense mutations might decrease SGLT2 affinity for glucose and patients will display type B glucosuria (44). Compound heterozygosity for SGLT2 mutations, however, is probably the reason that many past cases of severe glucosuria could not be clearly classified into type A or B and that a broad spectrum of impaired tubular glucose transport has been found in those patients. We therefore propose that individuals with FRG be characterized according to the amount of glucose excreted in a 24-h urine collection, normalized for body surface: Mild renal glucosuria for <10 g/1.73 m2 per d and severe renal glucosuria for ≥10 g/1.73 m2 per d.

Clinical Consequences of FRG

Overall, patients with renal glucosuria have not been shown to be affected by severe clinical consequences, and this entity is considered a benign condition, more a phenotype than a disease. For example, polyuria and enuresis and later a mild growth and pubertal maturation delay were the only manifestations observed during a follow-up period of 30 yr (53). Several other manifestations have occasionally been reported in severe forms of FRG, such as episodic dehydration and ketosis during pregnancy and starvation (40), the presence of several autoantibodies without clinical evidence of autoimmune disease (54), or an increased incidence of urinary tract infections (54,55). Activation of the renin-angiotensin-aldosterone system, secondary to natriuresis and possible extracellular volume depletion, has also been observed (45,46).

Hypercalciuria was identified as an accompanying feature in five of seven male children with renal glucosuria in one study (56), and in one patient who displayed severe renal glucosuria, an elevated calcium/creatinine ratio on spot urine was also described (53). The reason for this finding remains unknown.

There are several case reports of selective aminoaciduria associated with renal glucosuria, involving aspartic acid in one; glutamic acid, citrulline, and alanine in another; and arginine, carnosine, and taurine in yet another patient (57,58). Six children who had glucosuria, were from three pedigrees, and were homozygous for the novel SGLT2 p.K321R mutation were shown to have generalized aminoaciduria not accompanied by any other proximal tubular transport abnormalities (51). It was postulated that aminoaciduria could be secondary to glucosuria and not a primary effect of the SGLT2 mutation. Indeed, aminoaciduria has been found not only in MODY3 but also in types 1 and 2 diabetes, where it correlated positively with the amount of glucosuria (59). The proposed mechanism is that glucosuria is causing depolarization and dissipation of the electric gradient of sodium-dependent amino acid transporters in the proximal renal tubule.

SGLT2 Inhibition: A New Option for the Treatment of Type 2 Diabetes

Type 2 diabetes is characterized by hyperglycemia that results both from peripheral resistance to the action of insulin and from progressive failure of pancreatic β cell function (60). Chronic hyperglycemia of diabetes can lead to microvascular and macrovascular complications and also contributes, by means of glucotoxicity, to β cell dysfunction and insulin resistance, which aggravates the disease process (61). A novel strategy to reduce hyperglycemia is to target renal glucose excretion by inhibiting SGLT2. Evidence for such a beneficial effect comes not only from patients with FRG but also from studies of phlorizin, a natural product isolated from the root bark of the apple tree and known since the 19th century to cause glucosuria. When phlorizin was administered to partially pancreatectomized rats, the hyperglycemia was corrected without changing insulin levels, and both insulin sensitivity (62) and insulin secretion (63) were restored to normal. This provided the first evidence that hyperglycemia per se can lead to the development of insulin resistance. Despite demonstrating utility as an antihyperglycemic agent in several rodent models of diabetes, phlorizin was discontinued because it was readily hydrolyzed and poorly absorbed by the intestine, and it inhibited SGLT1 equally as well as SGLT2 (64). Furthermore, its active metabolite, phloretin, inhibits nonspecifically other glucose transporters.

Several selective inhibitors of SGLT2 have been developed to overcome the disadvantages of phlorizin. In a variety of animal models, they have been shown to induce glucosuria, lower blood glucose without altering insulin levels, improve insulin sensitivity, and reduce hepatic glucose output (6569). Some are now under evaluation in clinical trials, and published data are available for dapagliflozin, which is 1200-fold more selective for SGLT2 than SGLT1. When administered for 14 d to drug-naive or metformin-treated patients with type 2 diabetes, dapagliflozin induced a dosage-dependent increase in urinary glucose excretion, reaching a maximum of 70 g/d, and improved fasting blood glucose and glucose tolerance (70). In a more prolonged study, a total of 348 drug-naive patients with type 2 diabetes were randomly assigned to receive 2.5, 5.0, 10.0, 20.0, or 50.0 mg of dapagliflozin; 1.5 g of metformin; or placebo (71). Significant reduction of glycosylated hemoglobin, fasting plasma glucose, and body weight had occurred by the end of the study. The compound was found to have a mild diuretic effect with a decrease in systolic BP. In the short-duration treatment trial with dapagliflozin previously reported, an increase in urinary sodium was initially observed, returning to baseline by day 13 (70). In the pilot study that enrolled 348 patients with type 2 diabetes, it was shown that dapagliflozin displayed a dosage-dependent mild diuretic effect as assessed by daily urine output (71). Unfortunately, urinary sodium was not reported, so we can only speculate whether this diuretic effect was a consequence of glucosuric osmosis or, alternatively, dependent of true natriuresis reflecting the failure of the distal nephron to compensate for the Na+ proximal losses. In any circumstance, no changes in serum sodium (namely hypernatremia) were reported, leading to the impression that the increase in free water clearance is clinically irrelevant.

In addition, treated patients experienced sustained weight loss. Hypoglycemic episodes were similar when compared with the metformin-treated group, but the incidence of genital infections was higher.

Of note, both studies with dapagliflozin reported incomplete inhibition of SGLT2 with lower levels of glucosuria than in the most severe forms of FRG. It is possible that the accumulating tubular glucose competes with dapagliflozin for SGLT2 binding, thereby limiting the degree of inhibition.

Inhibition of renal glucose absorption may provide several advantages in the treatment of patients with type 2 diabetes. Unlike antidiabetic drugs that cause weight gain, the daily caloric loss of 100 to 300 kcal associated with SGLT2 inhibition may help patients actually to lose weight. They can also be expected to have a lower risk for developing hypoglycemia, an adverse effect often seen with insulin or insulin secretagogues. The mild diuretic effect observed may make SGLT2 inhibitors the preferred class of drugs to be used in conjunction with thiazolidinediones, which have been shown to cause fluid retention, especially in the presence of heart failure. Finally, the diuretic effect may contribute to BP control. Inhibition of SGLT2 is anticipated to be safe and free of undue consequences for patients, at least from chronic glucosuria. This can be deduced from the observation of patients who have FRG and in whom naturally occurring mutations of SGLT2 manifest as a mostly benign disorder.


Familial renal glucosuria is currently accepted to be a benign hereditary condition that, in the majority of cases, does not pose serious physical/clinical consequences to affected individuals. Mutations in SLC5A2 (the SGLT2-coding gene) underlie most, if not all, cases of FRG. Inherited as a co-dominant entity, there is, however, variable expressivity. Even in its infrequent severe forms, characterized by complete absence of tubular glucose resorption, clinical manifestations are rare. On the basis of these observations and ongoing clinical studies, inhibition of SGLT2 may be a feasible way to treat patients with type 2 diabetes.


J.C. has received consulting fees from AstraZeneca/Bristol-Myers Squibb and Johnson and Johnson.

We thank William Watkins of PPSI for editorial assistance on the manuscript. This assistance was funded by Bristol-Myers Squibb.

Published online ahead of print. Publication date available at www.cjasn.org.


1. Brown GK: Glucose transporters: Structure, function and consequences of deficiency. J Inherit Metab Dis 23: 237–246, 2000
2. Wright EM, Hirayama BA, Loo DF: Active sugar transport in health and disease. J Intern Med 261: 32–43, 2007
3. Kloeckener-Gruissem B, Vandekerckhove K, Nurnberg G, Neidhardt J, Zeitz C, Nurnberg P, Schipper I, Berger W: Mutation of solute carrier SLC16A12 associates with a syndrome combining juvenile cataract with microcornea and renal glucosuria. Am J Hum Genet 82: 772–779, 2008
4. Wright EM, Turk E: The sodium/glucose cotransport family SLC5. Pflugers Arch 447: 510–518, 2004
5. Ganapathy V, Thangaraju M, Gopal E, Martin PM, Itagaki S, Miyauchi S, Prasad PD: Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J 10: 193–199, 2008
6. Hediger MA, Coady MJ, Ikeda TS, Wright EM: Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature 330: 379–381, 1987
7. Kanai Y, Lee WS, You G, Brown D, Hediger MA: The human kidney low affinity Na+/glucose cotransporter SGLT2: Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93: 397–404, 1994
8. Diez-Sampedro A, Hirayama BA, Osswald C, Gorboulev V, Baumgarten K, Volk C, Wright EM, Koepsell H: A glucose sensor hiding in a family of transporters. Proc Natl Acad Sci U S A 100: 11753–11758, 2003
9. Quamme GA, Freeman HJ: Evidence for a high-affinity sodium-dependent D-glucose transport system in the kidney. Am J Physiol 253: F151–F157, 1987
10. Turner RJ, Moran A: Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule: Evidence from vesicle studies. Am J Physiol 242: F406–F414, 1982
11. Turner RJ, Moran A: Further studies of proximal tubular brush border membrane D-glucose transport heterogeneity. J Membr Biol 70: 37–45, 1982
12. Turner RJ, Moran A: Stoichiometric studies of the renal outer cortical brush border membrane D-glucose transporter. J Membr Biol 67: 73–80, 1982
13. You G, Lee WS, Barros EJ, Kanai Y, Huo TL, Khawaja S, Wells RG, Nigam SK, Hediger MA: Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 270: 29365–29371, 1995
14. Wright EM: Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 280: F10–F18, 2001
15. Turk E, Wright EM: Membrane topology motifs in the SGLT cotransporter family. J Membr Biol 159: 1–20, 1997
16. Wright EM, Loo DD, Hirayama BA, Turk E: Surprising versatility of Na+-glucose cotransporters: SLC5. Physiology (Bethesda) 19: 370–376, 2004
17. Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA: Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol 263: F459–F465, 1992
18. Faham S, Watanabe A, Besserer GM, Cascio D, Specht A, Hirayama BA, Wright EM, Abramson J: The crystal structure of a sodium galactose transporter reveals mechanistic insights into Na+/sugar symport. Science 321: 810–814, 2008
19. Loo DD, Hirayama BA, Meinild AK, Chandy G, Zeuthen T, Wright EM: Passive water and ion transport by cotransporters. J Physiol 518: 195–202, 1999
20. Loo DD, Wright EM, Zeuthen T: Water pumps. J Physiol 542: 53–60, 2002
21. Panayotova-Heiermann M, Wright EM: Mapping the urea channel through the rabbit Na(+)-glucose cotransporter SGLT1. J Physiol 535: 419–425, 2001
22. Gagnon MP, Bissonnette P, Deslandes LM, Wallendorff B, Lapointe JY: Glucose accumulation can account for the initial water flux triggered by Na+/glucose cotransport. Biophys J 86: 125–133, 2004
23. Zeuthen T, Zeuthen E, Klaerke DA: Mobility of ions, sugar, and water in the cytoplasm of Xenopus oocytes expressing Na(+)-coupled sugar transporters (SGLT1). J Physiol 542: 71–87, 2002
24. Kellett GL, Brot-Laroche E: Apical GLUT2: A major pathway of intestinal sugar absorption. Diabetes 54: 3056–3062, 2005
25. Mogensen CE: Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 28: 101–109, 1971
26. Chin E, Zamah AM, Landau D, Gronbcek H, Flyvbjerg A, LeRoith D, Bondy CA: Changes in facilitative glucose transporter messenger ribonucleic acid levels in the diabetic rat kidney. Endocrinology 138: 1267–1275, 1997
27. Kamran M, Peterson RG, Dominguez JH: Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol 8: 943–948, 1997
28. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J: Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54: 3427–3434, 2005
29. Freitas HS, Anhe GF, Melo KF, Okamoto MM, Oliveira-Souza M, Bordin S, Machado UF: Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: Involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 149: 717–724, 2008
30. Freitas HS, D'Agord SB, da Silva RS, Okamoto MM, Oliveira-Souza M, Machado UF: Insulin but not phlorizin treatment induces a transient increase in GLUT2 gene expression in the kidney of diabetic rats. Nephron Physiol 105: 42–51, 2007
31. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, Southam L, Cox RD, Lathrop GM, Boriraj VV, Chen X, Cox NJ, Oda Y, Yano H, Le Beau MM, Yamada S, Nishigori H, Takeda J, Fajans SS, Hattersley AT, Iwasaki N, Hansen T, Pedersen O, Polonsky KS, Bell GI: Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 384: 455–458, 1996
32. Menzel R, Kaisaki PJ, Rjasanowski I, Heinke P, Kerner W, Menzel S: A low renal threshold for glucose in diabetic patients with a mutation in the hepatocyte nuclear factor-1alpha (HNF-1alpha) gene. Diabet Med 15: 816–820, 1998
33. Pontoglio M, Prie D, Cheret C, Doyen A, Leroy C, Froguel P, Velho G, Yaniv M, Friedlander G: HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO Rep 1: 359–365, 2000
34. Pontoglio M, Sreenan S, Roe M, Pugh W, Ostrega D, Doyen A, Pick AJ, Baldwin A, Velho G, Froguel P, Levisetti M, Bonner-Weir S, Bell GI, Yaniv M, Polonsky KS: Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice. J Clin Invest 101: 2215–2222, 1998
35. Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, Babinet C, Yaniv M: Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 84: 575–585, 1996
36. Hjarne V: Study of orthoglycaemic glycosuria with particular reference to its hereditability. Acta Med Scand 67: 422–571, 1927
37. Crombie DL: Incidence of glycosuria and diabetes. Proc R Soc Med 55: 205–207, 1962
38. Marble A: Incidence of glycosuria and diabetes. Med Clin N Am 31: 313, 1947
39. Reubi F: Glucose titration in renal glucosuria. In: CIBA Foundation Symposium on the Kidney, edited by Lewis AA, Wolstenhome GE London, JA Churchill, Ltd., 1954, pp 96–106
40. Oemar BS, Byrd DJ, Brodehl J: Complete absence of tubular glucose reabsorption: A new type of renal glucosuria (type 0). Clin Nephrol 27: 156–160, 1987
41. Khachadurian AK, Khachadurian LA: The inheritance of renal glycosuria. Am J Hum Genet 16: 189–194, 1964
42. Elsas LJ, Rosenberg LE: Familial renal glycosuria: A genetic reappraisal of hexose transport by kidney and intestine. J Clin Invest 48: 1845–1854, 1969
43. Santer R, Kinner M, Schneppenheim R, Hillebrand G, Kemper M, Ehrich J, Swift P, Skovby F, Schaub J: The molecular basis of renal glucosuria: Mutations in the gene for a renal glucose transporter (SGLT2) [Abstract]. J Inherit Metab Dis 23[Suppl 1]: 178, 2000
44. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, Li VS, Neuhaus T, Skovby F, Swift PG, Schaub J, Klaerke D: Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14: 2873–2882, 2003
45. Calado J, Loeffler J, Sakallioglu O, Gok F, Lhotta K, Barata J, Rueff J: Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int 69: 852–855, 2006
46. Calado J, Sznajer Y, Metzger D, Rita A, Hogan MC, Kattamis A, Scharf M, Tasic V, Greil J, Brinkert F, Kemper MJ, Santer R: Twenty-one additional cases of familial renal glucosuria: Absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol Dial Transplant 23: 3874–3879, 2008
47. van den Heuvel LP, Assink K, Willemsen M, Monnens L: Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 111: 544–547, 2002
48. Calado J, Soto K, Clemente C, Correia P, Rueff J: Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria. Hum Genet 114: 314–316, 2004
    49. Francis J, Zhang J, Farhi A, Carey H, Geller DS: A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria. Nephrol Dial Transplant 19: 2893–2895, 2004
      50. Kleta R, Stuart C, Gill FA, Gahl WA: Renal glucosuria due to SGLT2 mutations. Mol Genet Metab 82: 56–58, 2004
        51. Magen D, Sprecher E, Zelikovic I, Skorecki K: A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria. Kidney Int 67: 34–41, 2005
        52. De Marchi S, Cecchin E, Basile A, Proto G, Donadon W, Jengo A, Schinella D, Jus A, Villalta D, De Paoli P: Close genetic linkage between HLA and renal glycosuria. Am J Nephrol 4: 280–286, 1984
        53. Scholl-Burgi S, Santer R, Ehrich JH: Long-term outcome of renal glucosuria type 0: The original patient and his natural history. Nephrol Dial Transplant 19: 2394–2396, 2004
        54. De Paoli P, Battistin S, Jus A, Reitano M, Villalta D, De Marchi S, Cecchin E, Basile A, Santini G: Immunological characterization of renal glycosuria patients. Clin Exp Immunol 56: 289–294, 1984
        55. De Marchi S, Cecchin E, Basile A, Proto G, Donadon W, Schinella D, Lengo A, De Paoli P, Jus A, Villalta D: Is renal glycosuria a benign condition? Proc Eur Dial Transplant Assoc 20: 681–685, 1983
        56. Schneider D, Gauthier B, Trachtman H: Hypercalciuria in children with renal glycosuria: Evidence of dual renal tubular reabsorptive defects. J Pediatr 121: 715–719, 1992
        57. Gotzsche O: Renal glucosuria and aminoaciduria. Acta Med Scand 202: 65–67, 1977
        58. Sankarasubbaiyan S, Cooper C, Heilig CW: Identification of a novel form of renal glucosuria with overexcretion of arginine, carnosine, and taurine. Am J Kidney Dis 37: 1039–1043, 2001
        59. Bingham C, Ellard S, Nicholls AJ, Pennock CA, Allen J, James AJ, Satchell SC, Salzmann MB, Hattersley AT: The generalized aminoaciduria seen in patients with hepatocyte nuclear factor-1alpha mutations is a feature of all patients with diabetes and is associated with glucosuria. Diabetes 50: 2047–2052, 2001
        60. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 31: S55–S60, 2008
        61. Poitout V, Robertson RP: Glucolipotoxicity: Fuel excess and beta-cell dysfunction. Endocr Rev 29: 351–366, 2008
        62. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA: Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79: 1510–1515, 1987
        63. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA: Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 80: 1037–1044, 1987
        64. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J: Phlorizin: A review. Diabetes Metab Res Rev 21: 31–38, 2005
        65. Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, Matsumoto M, Saito A, Tsujihara K, Anai M, Asano T, Kanai Y, Endou H: T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48: 1794–1800, 1999
        66. Adachi T, Yasuda K, Okamoto Y, Shihara N, Oku A, Ueta K, Kitamura K, Saito A, Iwakura I, Yamada Y, Yano H, Seino Y, Tsuda K: T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism 49: 990–995, 2000
          67. Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M: Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 320: 323–330, 2007
            68. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M: Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 327: 268–276, 2008
              69. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, Wetterau JR, Washburn WN, Whaley JM: Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57: 1723–1729, 2008
              70. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M: Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 85: 513–519, 2009
              71. List JF, Woo V, Morales E, Tang W, Fiedorek FT: Sodium-glucose co-transport inhibition with dapagliflozin in type 2 diabetes mellitus. Diabetes Care 32: 650–657, 2009
              72. Brodehl J, Oemar BS, Hoyer PF: Renal glucosuria. Pediatr Nephrol 1: 502–508, 1987
                Copyright © 2010 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.